Opinion | Welcome to the Stephen Miller Presidency
A facts-only brief, written by a local AI model from this article in The Wall Street Journal, November 22, 2026. It may contain mistakes, and it is not the article: the full story is at wsj.com.
An opinion essay argues that the White House withdrew Dr. Heidi Overton’s nomination to lead the Food and Drug Administration due to internal opposition from Stephen Miller and his allies, rather than a lack of Senate support. The author contends that this move signals Miller’s intent to prioritize his own agenda over institutional stability, potentially leaving the agency without a permanent head for the remainder of the presidential term. The piece asserts that Overton was removed after a scheduled Senate Health Committee vote was canceled late Tuesday, despite officials having rallied conservative groups in her favor.
Background
- Louisiana Senator Bill Cassidy, who chairs the Health Committee, stated he was confused by the withdrawal because he believed Overton had sufficient support for confirmation.
- Calley Means, a former adviser to HHS Secretary Robert F. Kennedy Jr., launched a media campaign against Overton, accusing her of blocking his policy priorities and supporting a Justice Department brief in a Supreme Court case involving Bayer.
- Trump administration officials stated that Overton played a minor role in the legal matter, while Means argued the Justice Department should have consulted Secretary Kennedy.
- The essay notes that Overton previously served in the White House Domestic Policy Council and at the America First Policy Institute before being tapped for the FDA in August.
Read the full article at wsj.com
More from Sunday, November 22:
Write a comment